Argenx (ARGX)
(Delayed Data from NSDQ)
$528.50 USD
-4.50 (-0.84%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $528.32 -0.18 (-0.03%) 5:08 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 1 - 20 ( 307 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Quiets the Doubters With a Big Beat in 2Q; Price Target Up to $533
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
argenx Answers Many Questions at RD Day; Raise Price Target to $504
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Red RHOver Red RHOver, Let Sjogren?s Come Over
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Allo, Bringing New Potluck Dishes to the II CART
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Cartesian Won''t Knock Vyvgart Off its Course in gMG
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Survey Says: CIDP Kicking Vyvgart Up More Than a Notch
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Additional Positive Data Of Empasiprubart To Treat MMN; Price Target up to $490
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Kicking Off the Summer Season With a Key Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D